Related Experiment Video
Updated: Jun 12, 2026

Cellular Redox Profiling Using High-content Microscopy
Published on: May 14, 2017
Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally
Marilyn J Crain1, Miriam C Chernoff, James M Oleske
1University of Alabama School of Medicine, Birmingham, AL 35233, USA. mcrain@peds.uab.edu
Insights
Mitochondrial dysfunction is common in children with perinatal HIV infection, particularly with certain antiretroviral drugs like stavudine and lamivudine. These findings highlight potential drug toxicities requiring further investigation.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Mitochondrial medicine
Background:
- Mitochondrial dysfunction is linked to HIV infection and antiretroviral therapy (ART).
- Limited research exists on mitochondrial dysfunction in children with perinatal HIV.
- This study aimed to determine the incidence of clinically defined mitochondrial dysfunction in this population.
Purpose of the Study:
- To estimate the incidence of clinically defined mitochondrial dysfunction in children with perinatal HIV infection.
- To investigate the association between nucleoside reverse-transcriptase inhibitor (NRTI) use and mitochondrial dysfunction.
Main Methods:
- Prospective cohort study (Pediatric AIDS Clinical Trials Group protocols 219 and 219C) from 1993-2004.
- Utilized two clinical case definitions for mitochondrial dysfunction.
- Logistic regression analyzed associations between NRTI use and mitochondrial dysfunction.
Main Results:
- 33.5% of 2931 children met criteria for possible mitochondrial dysfunction.
- Mortality was highest (20%) in children meeting both case definitions.
- Stavudine use (OR, 3.44) and stavudine-didanosine (OR, 2.23) increased risk; lamivudine and lamivudine-stavudine also associated with increased risk.
Conclusions:
- Nucleoside reverse-transcriptase inhibitor (NRTI) use, particularly stavudine and lamivudine, is associated with mitochondrial dysfunction in children with perinatal HIV.
- Further research is needed to understand the mechanisms of NRTI-related mitochondrial toxicities.
Background:
Mitochondrial dysfunction has been associated with both human immunodeficiency virus (HIV) infection and exposure to antiretroviral therapy. Mitochondrial dysfunction has not been widely studied in HIV-infected children. We estimated the incidence of clinically defined mitochondrial dysfunction among children with perinatal HIV infection.
Methods:
Children with perinatal HIV infection enrolled in a prospective cohort study (Pediatric AIDS Clinical Trials Group protocols 219 and 219C) from 1993 through 2004 were included. Two clinical case definitions of mitochondrial dysfunction, the Enquête Périnatale Française criteria and the Mitochondrial Disease Classification criteria, were used to classify signs and symptoms that were consistent with possible mitochondrial dysfunction. Adjusted odds ratios of the associations between single and dual nucleoside reverse-transcriptase inhibitor use and possible mitochondrial dysfunction were estimated using logistic regression.
Results:
Overall, 982 (33.5%) of 2931 children met 1 or both case definitions of possible mitochondrial dysfunction. Mortality was highest among the 96 children who met both case definitions (20%). After adjusting for confounders, there was a higher risk of possible mitochondrial dysfunction among children who received stavudine regardless of exposure to other medications (odds ratio, 3.44 [95% confidence interval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.23 [95% confidence interval, 1.19-4.21]). Exposure to lamivudine and to lamivudine-stavudine were also associated with an increased risk of mitochondrial dysfunction.
Conclusions:
Receipt of nucleoside reverse-transcriptase inhibitors, especially stavudine and lamivudine, was associated with possible mitochondrial dysfunction in children with perinatal HIV infection. Further studies are warranted to elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Retrovirus Life Cycles
Cytomegalovirus Disease
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...

